Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. For example, the sale of Horizon Therapeutics to Amgen for approximately $28 billion was the third-largest all-cash transaction in the pharmaceutical sector in history.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Peak Frameworks

SEPTEMBER 19, 2023

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. company to hit a $1 trillion valuation , it directly benefited shareholders. By virtue of their ownership, they possess a direct financial interest in the company's success.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Cooley M&A

JANUARY 22, 2021

The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion. While deal value was down for the year, deal volume was relatively stable (down only 2.0%

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

M&A Leadership Council

JUNE 12, 2023

Second, impact to deal valuation or terms. Concerning valuation or deal terms, the earlier you detect a breach or a strong possibility of a breach, the better so you can help corporate development decide how best to address the issues. MH: We often talk about due diligence findings in three successive phases.

IT 52

IT M&A Securities Insurance 52

M&A Leadership Council

SEPTEMBER 9, 2021

Second, impact to deal valuation or terms. Concerning valuation or deal terms, the earlier you detect a breach or a strong possibility of a breach, the better so you can help corporate development decide how best to address the issues. MH: We often talk about due diligence findings in three successive phases.

IT 52

IT M&A Securities Insurance 52

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40